BioSpace News Archive

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent, which will be issued to the Company, titled “Devices and Methods for On-Line Whole Blood Treatment” regarding the Company’s Selective Target Anti

Intravacc, one of the world’s leading translational research and development vaccine institutes, with an extensive track record in developing viral and bacterial vaccines, has announced more details on its development of an intranasal vaccine against COVID-19.

MYOS RENS Technology Inc. (“MYOS”) (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, announced today that it wi

Data-driven food allergy diagnostics company, AllerGenis LLC, today announced its activities at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress 2020, being held virtually from June 6th

OBIO’s Health to Business Bridge™ Program (H2BB) prepares new hires for careers in Ontario’s health science industry, helping companies build for the future in an innovative sector poised for growth.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solu

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (“Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (“COVID-19”) outb

Alcami, a United States -based contract development and manufacturing organization (CDMO), announced today the appointment of Walter J. Kaczmarek III as Chief Executive Officer. Mr. Kaczmarek, who has over 30 years of experience in the pharmaceutical industry, will focus on advancing Alcami’s next phase of strategic growth.

The date and time of the 2020 Annual Meeting remain 8:30 a.m. ET on June 17, 2020 – – To participate in the virtual meeting, stockholders must register by 11:59 ET on June 15, 2020 –

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the SELECT-COMPARE (upadacitinib, 15 mg in combination with methotrexate [MTX]) and SELECT-MONOTHERAPY